Doris Day
New York, NYNPI 1851384028
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $197,715 of the $309,824 with a category attached, or 63.8%. 29 manufacturers reported payments, led by Merz North America, Inc. at 36.0% of the total.
Across 521 payments — averaging $594.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$111K
- AbbVie$57K
- Revance Therapeutics, Inc.$52K
- Galderma Laboratories, L.p.$33K
- Solta Medical, A Division Of Bausch Health US, LLC$24K
- Endo Pharmaceuticals Inc.$10K
- plus $23K from 23 others
What the payments were for
- Consulting fees$197,71564%
- Speaking & faculty fees$67,74722%
- Travel & lodging$24,4968%
- Food & beverage$19,2516%
- Education$6160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 86 | $111,487 |
| AbbVie(2 entities) | 105 | $56,709 |
| Revance Therapeutics, Inc. | 14 | $51,806 |
| Galderma Laboratories, L.p. | 76 | $33,422 |
| Solta Medical, A Division Of Bausch Health US, LLC | 7 | $23,809 |
| Endo Pharmaceuticals Inc. | 14 | $9,657 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 33 | $9,466 |
| Dermira, Inc. | 6 | $4,426 |
| Botanix SB Inc | 4 | $2,274 |
| EPI Health, LLC | 9 | $1,705 |
| Almirall LLC | 2 | $973 |
| Incyte Corporation | 36 | $901 |
| Johnson & Johnson | 14 | $474 |
| UCB, Inc. | 23 | $465 |
| Lilly USA, LLC | 19 | $416 |
| Amgen | 15 | $396 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $350 |
| Sun Pharmaceutical Industries Inc. | 17 | $200 |
| Pfizer | 8 | $176 |
| Journey Medical Corporation | 9 | $164 |
| LEO Pharma Inc. | 5 | $106 |
| Novartis | 3 | $95 |
| Sanofi | 3 | $92 |
| Dermavant Sciences, Inc. | 3 | $78 |
| Mayne Pharma Commercial LLC | 4 | $69 |
| Organon | 2 | $48 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Fidia Pharma USA Inc. | 1 | $18 |
| Sebela Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$66,422
- DAXXIFY$51,539
- BOTOX COSMETIC$31,253
- ALTRENO$8,850
- QBREXZA$4,336
- BOTOX$2,579
- SOFDRA$2,200
- Sitavig$1,500
- Cloderm$1,500
- Minolira 105mg$1,500
- Minolira 135mg$1,500
- Rhofade$1,500
- Sumadan Wash$350
- ASCLERA$139
- ORACEA$133
- DYSPORT$130
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 49 | $1,492 |
| Hydrocortisone | 17 | $89 |
| Triamcinolone Acetonide | 14 | $71 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.